Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Madeline Richey
Observed name:
M. Richey
Institution:
Flatiron Health (United States)
Observed institutions:
Flatiron Health (United States),
Columbia University
ORCID:
0000-0002-5161-5182
Observed ORCID:
0000-0002-5161-5182
OpenAlex ID:
A5001569477
A Natural Language Processing Algorithm to Improve Completeness of ECOG Performance Status in Real-World Data
2023
·
Aaron B. Cohen
, Andrej Rosic
, et al.
·
Applied Sciences
·
24
PDF
Automated Electronic Health Record–Based Tool for Identification of Patients With Metastatic Disease to Facilitate Clinical Trial Patient Ascertainment
2021
·
Jeffrey Kirshner
, Kelly Cohn
, et al.
·
JCO Clinical Cancer Informatics
·
24
Abemaciclib Persistence in Patients with HR+, HER2−, Node-Positive Early Breast Cancer: a Real-World Analysis
2025
·
Kathryn Hudson
, Wambui Gathirua-Mwangi
, et al.
·
Oncology and Therapy
·
3
PDF
Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study
2025
·
Dana M. Chase
, Maya Hanna
, et al.
·
Oncology and Therapy
·
3
PDF
Abstract P1-11-29: Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval
2025
·
Kathryn Hudson
, Wambui Grace Gathirua-Mwangi
, et al.
·
Clinical Cancer Research
·
2
An automated EHR-based tool to facilitate patient identification for biomarker-driven trials.
2021
·
Shailendra Lakhanpal
, Kailee Hawkins
, et al.
·
Journal of Clinical Oncology
·
2
An automated EHR-based tool for identification of patients (pts) with metastatic disease to facilitate clinical trial pt ascertainment.
2020
·
Jeffrey J. Kirshner
, Kelly Cohn
, et al.
·
Journal of Clinical Oncology
·
2
Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma
2025
·
Madeline Richey
, Christina Fullerton
, et al.
·
Advances in Therapy
·
1
Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States
2026
·
Jhanelle E. Gray
, Kelli Thoele
, et al.
·
Lung Cancer
Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
2026
·
Ben Tran
, Tanya Dorff
, et al.
·
Clinical Genitourinary Cancer
US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study
2026
·
John Nakayama
, Madeline Richey
, et al.
·
Future Oncology
Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with advanced urothelial cancer.
2026
·
Emily Nash Smyth
, Madeline Richey
, et al.
·
Journal of Clinical Oncology
PDF
Treatment patterns and survival outcomes among lutetium 177–experienced patients with metastatic castration-resistant prostate cancer.
2026
·
Ben Tran
, Tanya B. Dorff
, et al.
·
Journal of Clinical Oncology
PDF
EP.17.33 Evolving Treatment Patterns in Early-Stage Non-Small Cell Lung Cancer in the United States
2025
·
J.E. Gray
, K. Thoele
, et al.
·
Journal of Thoracic Oncology
Real-world biomarker testing differences and treatment choice in advanced ovarian cancer
2025
·
John Nakayama
, Madeline Richey
, et al.
·
Gynecologic Oncology
P004: Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval
2025
·
K. Hudson
, W. Gathirua-Mwangi
, et al.
·
The Breast
The potential impact of excluding patients with stage III epithelial ovarian cancer and no postoperative visible residual disease from the PRIMA/ENGOT-OV26/GOG-3012 trial: The AR1ZE real-world study of niraparib first-line maintenance therapy
2024
·
Dana Chase
, Maya Hanna
, et al.
·
Gynecologic Oncology
135P Characteristics and dosing patterns of US patients diagnosed with HR+/HER2- early breast cancer initiating abemaciclib at a lower dose than the approved 150mg BID
2024
·
L.M. Spring
, W.G. Gathirua-Mwangi
, et al.
·
ESMO Open
PDF
RWD158 Development of a Derived Induction Failure and Relapse (DIFR) Variable for Acute Myeloid Leukemia (AML) Using Real-World (RW) Data from an Electronic Health Record (EHR)-Derived Database
2023
·
C. Fullerton
, Q. Zhang
, et al.
·
Value in Health
210 Big data provides insight into alopecia areata comorbidities
2017
·
M. Richey
, L. Petukhova
·
Journal of Investigative Dermatology
Show more works
View as search
Works count:
20
Citation count:
65
H-index:
3
I10-index:
2
Year
Topic
Type